Logo

POM

POMDOCTOR Ltd

POM

POMDOCTOR Ltd • NASDAQ
$4.32 ▲ 10.77% (+0.42)
Market Cap $461.98 M
52w High $6.43
52w Low $3.35
Dividend Yield 0%
P/E -108
Volume 322.18K
Outstanding Shares 106.94M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $7.652M ▼ $46.228M ▼ $2.141B ▲ $-2.263B ▼
Q2-2024 $12.714M $56.261M $2.079B $-2.187B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow

Five-Year Company Overview

Income Statement

Income Statement POMDOCTOR shows a classic early-stage profile: revenue is small but steadily rising each year, while profitability is still far out of reach. The company does generate some gross profit, but the margin is thin and not yet strong enough to cover operating costs. Operating results have hovered around break-even at times but remain negative overall, and net losses are large relative to the current scale of the business. There is no clear pattern of losses shrinking, which suggests that the economic model still needs more scale or cost discipline before it can support sustainable profits.

Balance Sheet

Balance Sheet The balance sheet is a weak point. The company operates with a very small asset base and only a modest cash cushion, yet carries a much larger level of debt. Shareholders’ equity is deeply negative and has been drifting further downward, reflecting cumulative losses and heavy reliance on borrowing and new capital. This structure leaves limited buffer against shocks and means the business is quite dependent on continued support from lenders and investors to stay on track with its plans.

Cash Flow

Cash Flow Cash flow mirrors the income statement: the core business consumes cash rather than generates it. Operating cash flow has been consistently negative, though the outflows have not exploded, suggesting controlled but ongoing cash burn. Because capital spending is minimal, free cash flow is essentially the same as operating cash flow, typical of an asset-light, platform-based model. The combination of steady burn and a small cash balance highlights a need for external funding to support operations until the business can move closer to break-even.

Competitive Edge

Competitive Edge Competitively, POMDOCTOR has carved out a focused niche in chronic disease management rather than broad telehealth. This specialization, together with strong repeat behavior from patients and high retention of doctors, creates a relatively sticky ecosystem. The integrated pharmaceutical supply chain and end-to-end service from consultation to medication delivery add convenience that can deepen loyalty and create network effects as more doctors and patients join. However, the company is competing in China against much larger and better-capitalized digital health and e-commerce players, which can put pressure on pricing, marketing, and innovation speed. Maintaining differentiation and engagement will be critical in this environment.

Innovation and R&D

Innovation and R&D Innovation centers on a one-stop digital platform that lives where users already are, particularly through WeChat, backed by a dedicated doctor portal and pharmacist verification system. This setup streamlines the full journey from consultation to prescription fulfillment, which is especially valuable for chronic conditions requiring frequent follow-up and medication refills. The roadmap includes expanding to phone and video visits and eventually using data and artificial intelligence to personalize care, all funded in part by recent capital raising. The opportunity is significant, but the company will be innovating against rivals with far larger R&D budgets, making focused, high-impact development more important than chasing every new feature.

Summary

Overall, POMDOCTOR is an early-stage digital healthcare platform with an appealing strategic focus—chronic disease management in a large and growing Chinese market—and encouraging engagement indicators from both doctors and patients. At the same time, the financial profile is fragile: small scale, persistent losses, a thin cushion of assets and cash, heavy use of debt, and deeply negative equity. The story hinges on whether the company can scale its platform, control costs, and strengthen its balance sheet while fending off powerful competitors. Future outcomes carry meaningful uncertainty, and the key variables to watch are user growth and retention, progress toward profitability, and access to additional funding on acceptable terms.

NEWS

October 17, 2025 · 1:47 PM UTC

Citi Appointed as Depositary Bank for POMDOCTOR LIMITED's ADR Program

Read more

October 10, 2025 · 5:15 PM UTC

POMDOCTOR LIMITED Announces Full Exercise and Closing of Underwriter's Over-Allotment Option

Read more

October 9, 2025 · 4:05 PM UTC

POMDOCTOR LIMITED Announces Closing of Initial Public Offering

Read more

October 8, 2025 · 8:00 AM UTC

POMDOCTOR LIMITED Announces Pricing of Initial Public Offering

Read more